REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS

被引：0
|
作者：
Abdallah, K. [1 ]
Kiani, P. [1 ]
Huys, I [1 ]
Claes, K. [1 ]
Simoens, S. [1 ]
机构：
[1] Katholieke Univ Leuven, B-3000 Leuven, Vbr, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PNS53
引用
收藏
页码：S771 / S771
页数：1
相关论文
共 50 条
  • [31] EVALUATING THE ADHERENCE TO ISPOR GUIDELINES IN GLOBALLY PUBLISHED BUDGET IMPACT ANALYSES OF NEW DRUGS: A TARGETED LITERATURE REVIEW
    Amaefule, A.
    Thakkar, K.
    Erb, R. S.
    Rascati, K. L.
    VALUE IN HEALTH, 2023, 26 (12) : S546 - S547
  • [32] EVALUATING THE ADHERENCE TO ISPOR GUIDELINES IN US PUBLISHED BUDGET IMPACT ANALYSES OF NEW DRUGS: A TARGETED LITERATURE REVIEW
    Amaefule, A. Q.
    Thakkar, K.
    Erb, R. S.
    Rascati, K. L.
    VALUE IN HEALTH, 2023, 26 (06) : S399 - S399
  • [33] Budget-Impact Analyses A Critical Review of Published Studies
    Orlewska, Ewa
    Gulacsi, Laszlo
    PHARMACOECONOMICS, 2009, 27 (10) : 807 - 827
  • [34] Vaccines are different: A systematic review of budget impact analyses of vaccines
    Loze, Priscilla Magalhaes
    Nasciben, Luciana Bertholim
    Christovam Sartori, Ana Marli
    Itria, Alexander
    Dutilh Novaes, Hillegonda Maria
    de Soarez, Patricia Coelho
    VACCINE, 2017, 35 (21) : 2781 - 2793
  • [35] A SYSTEMATIC REVIEW OF THE METHODOLOGICAL QUALITY OF NETWORK META-ANALYSES
    Chambers, J.
    Naci, H.
    Wouters, O.
    Pyo, J.
    Gunjal, S.
    Kennedy, I
    Hoey, M.
    Winn, A.
    Neumann, P. J.
    VALUE IN HEALTH, 2015, 18 (03) : A31 - A31
  • [36] REVIEW OF COST EFFECTIVENESS MODELS OF HIGH BUDGET IMPACT DRUGS
    Aggarwal, S.
    VALUE IN HEALTH, 2011, 14 (07) : A361 - A361
  • [37] Budget Impact Analysis of Diabetes Drugs: A Systematic Literature Review
    Luo, Zejun
    Ruan, Zhen
    Yao, Dongning
    Ung, Carolina Oi Lam
    Lai, Yunfeng
    Hu, Hao
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [38] REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS
    Aggarwal, S.
    White, N.
    Stevens, C. A.
    VALUE IN HEALTH, 2010, 13 (03) : A16 - A17
  • [39] THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS
    Divino, V
    DeKoven, M.
    Kim, T.
    Kleinrock, M.
    Wade, R. L.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A666 - A666
  • [40] Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
    Richard Manning
    PharmacoEconomics, 2020, 38 : 1373 - 1374
12345